Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.39 USD
+0.10 (4.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.38 -0.01 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Cardiff Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 46 | 40 | 29 | 19 | 17 |
Income After Depreciation & Amortization | -45 | -40 | -29 | -19 | -17 |
Non-Operating Income | 4 | 1 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -41 | -39 | -28 | -19 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -41 | -39 | -28 | -19 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -41 | -39 | -28 | -19 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -46 | -39 | -27 | -19 | -16 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -45 | -40 | -29 | -19 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.68 | 43.60 | 39.03 | 20.88 | 5.97 |
Diluted EPS Before Non-Recurring Items | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 |
Diluted Net EPS (GAAP) | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 |
Fiscal Year end for Cardiff Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.16 | 0.21 | 0.16 | 0.14 | 0.11 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.16 | 0.21 | 0.16 | 0.14 | 0.11 |
SG&A, R&D, and Dept/Amort Expenses | 12.71 | 11.14 | 10.49 | 10.96 | 12.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -12.55 | -10.93 | -10.33 | -10.82 | -12.21 |
Non-Operating Income | 0.77 | 0.92 | 0.99 | 1.09 | 1.06 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -11.78 | -10.01 | -9.34 | -9.73 | -11.15 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.78 | -10.01 | -9.34 | -9.73 | -11.15 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -11.78 | -10.01 | -9.34 | -9.73 | -11.15 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 44.83 | 44.68 | 44.46 | 44.68 | 44.68 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.22 | -0.21 | -0.22 | -0.25 |
Diluted Net EPS (GAAP) | -0.26 | -0.22 | -0.21 | -0.22 | -0.25 |